The dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin is widely used to treat type 2 diabetes, but researchers have recently found that it also has a therapeutic effect in renal and hepatic fibrosis. Here, DPP4 is linked to type 2 diabetes mellitus.